DIAVACS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://www.diavacs.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy
Phase 2
Withdrawn
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- DiaVacs, Inc.
- Registration Number
- NCT02354911
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Phase 1
- Conditions
- Treatment of Type I Diabetes Mellitus.
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- DiaVacs, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01947569
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
News
No news found